Tempest Announces Closing of Strategic Acquisition of Dual-Targeting CAR-T Assets

On February 4, 2026 Tempest Therapeutics, Inc. (Nasdaq: TPST) ("Tempest"), a clinical-stage biotechnology company with a pipeline of advanced strategic therapeutic assets, reported the closing of a previously announced transaction pursuant to which Tempest acquired certain dual-targeting chimeric antigen receptor (CAR)-T programs and obtained financing support from Factor Bioscience Inc. and its affiliates (collectively, "Factor") in an all-stock transaction resulting in a diverse portfolio including clinical-stage product candidates and an extended runway with multiple potential near-term milestones (the "Transaction").

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"I am excited to join the Tempest team and to have the opportunity to develop this innovative pipeline of potential therapies to treat a range of solid tumors and hematologic malignancies," said Dr. Matt Angel, President and Chief Executive Officer of Tempest. "I look forward to advancing the company’s vision of bringing important therapies to patients."

"The Board is pleased to announce the closing of this transaction, which not only provides increased financial stability for Tempest, but also the opportunity for potentially significant milestones over the next 12-18 months from both the legacy small molecule programs and the new cell therapy assets," said Stephen Brady, Chair of the Board.

"As Tempest moves into this next phase, we would like to thank Geoff Nichol and Mike Raab." Mr. Brady continued. "We are grateful for Geoff’s support, engagement and inquisitive mind since he joined the Board in 2021, and wish him continued success in his endeavors. Mike Raab has been our Chair since 2018, during which time he provided clear leadership, thoughtful perspectives, and significant contributions to Tempest throughout his tenure. We are thrilled that Mike will continue to serve on the Board, bringing the ongoing benefit of his experience and guidance to the company."

Key Takeaways:

Amezalpat (TPST-1120) remains Phase 3 ready in first-line liver cancer ("HCC"), supported by global regulatory agreement and positive randomized Phase 2 data. Tempest plans to pursue business development discussions to advance pivotal development.
TPST-2003: new dual-targeting CD19/BCMA CAR-T asset
Phase 1 complete in patients with relapsed/refractory multiple myeloma ("rrMM"), with data expected in 2026 and a biologics license application ("BLA") in China planned for 2027
Phase 1 currently enrolling patients with POEMS syndrome, with data expected in 2027 and a BLA in China planned for 2028
Tempest has global rights to TPST-2003 outside of China, India, Turkey and Russia, and plans to pursue a potential registrational study in rrMM in the U.S. starting in 2027
Pivotal data from the Chinese study expected to validate probability of success for the program, and rights include the right to reference data generated in support of the planned China BLA
All development activities in China to be funded by strategic partner
Tempest expects a Phase 2 study of TPST-1495 in familial adenomatous polyposis ("FAP") to enroll the first patient in Q1’26 and to be funded by the National Cancer Institute and operationalized by the Cancer Prevention Clinical Trials Network.
Plan to continue the development of additional new preclinical and research-stage pipeline programs:
TPST-2206: dual-targeting CD70/CD70 CAR-T for renal cell carcinoma
TPST-3003: allogeneic dual-targeting CD19/BCMA
TPST-3206: allogeneic dual-targeting CD70/CD70
Existing cash and an investment commitment from Factor is expected to provide a runway to mid-2027 and potentially through key data milestones.
Combined Pipeline

Tempest Therapeutics Combined Pipeline
Advisors

MTS Health Partners, L.P. served as financial advisor to Tempest, and Cooley LLP served as legal advisor. In addition, MTS Securities, LLC (an affiliate of MTS Health Partners, L.P.) provided an opinion to the board of directors of Tempest regarding the fairness of the purchase price to be paid by Tempest to Factor in connection with the Transaction, subject to the qualifications and limitations set forth therein. Morse, Barnes-Brown & Pendleton, P.C. served as legal advisor to Factor.

(Press release, Tempest Therapeutics, FEB 4, 2026, View Source [SID1234662478])

Coherus Oncology Announces Clinical Supply Agreement to Evaluate Tagmokitug in Combination with Pasritamig

On February 4, 2026 Coherus Oncology, Inc. (NASDAQ: CHRS) reported a clinical supply agreement with Johnson & Johnson to evaluate tagmokitug (CHS-114), Coherus Oncology’s investigational anti-CCR8 cytolytic monoclonal antibody, in combination with pasritamig, a T-cell engaging bispecific antibody, in a Phase 1b clinical study in patients with metastatic castration-resistant prostate cancer (mCRPC).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"This agreement is representative of our strategy to accelerate development of our pipeline through partnerships and differentiated combinations," said Denny Lanfear, Chairman and Chief Executive Officer at Coherus. "We continue to advance our strategic vision to build a portfolio of first-in-class and best-in-class therapies designed to deliver a step change in survival for patients with difficult-to-treat cancers."

Under the terms of the clinical supply agreement, Johnson & Johnson will provide pasritamig to Coherus, who will be the sponsor of the Phase 1b clinical trial. Johnson & Johnson and Coherus each retain all commercial rights to their respective compounds, including as monotherapy or as combination treatments.

(Press release, Coherus Oncology, FEB 4, 2026, View Source [SID1234662464])

Theralase® Provides Update on Bladder Cancer Clinical Study

On February 4, 2026 Theralase Technologies Inc. ("Theralase" or the "Company") (TSXV:TLT) (OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses, reported an update on the Phase II clinical study for bladder cancer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To date, 90 patients have been enrolled and treated with the Theralase Study Procedure, achieving the patient enrollment specified by the statistical analysis plan.

78 patients have completed the clinical study and were evaluated at all scheduled assessment visits or were prematurely removed by the principal investigator due to lack of response. There are 12 patients pending study completion.

Primary Endpoint Performance (CR at any Point in Time)
# % Confidence Interval (95%)
Complete Response ("CR") 56/87 64.4% [48.6, 80.2]
Total Response (CR and IR) 64/87 73.6% [56.7, 90.5]
Note: Indeterminate Response ("IR") is defined as negative cystoscopy (no evidence of Urothelial Cell Carcinoma ("UCC") in the bladder) and positive / suspicious urine cytology (detection of cancer in the urine, without a negative confirmatory bladder biopsy, suggesting UCC in the renal system other than the bladder).

Secondary Endpoint Performance (Duration of CR) (450 Days)
# % Confidence Interval (95%)
Complete Response 19/47 40.4% [23.8, 57.1]
Total Response 20/47 42.6% [26.6, 58.5]
Tertiary Endpoint Performance (Safety) (450 Days)
# %
Safety 78/78 100.0%
Note: Theralase believes all Serious Adverse Events ("SAEs") reported to date are unrelated or unlikely related to the Study Drug or Study Device.

These results exceed the International Bladder Cancer Group’s recommended guidelines of "clinically meaningful initial complete response rates for carcinoma in situ of at least 50% at 6 months and 30% at 12 months."1

Interim data from 47 patients indicates that complete response rates of 21.3% at both 2 and 3 years and 2.1% at 7 years were sustained.

Theralase will compile the clinical data in 2026 for presentation to Health Canada and FDA with an expected regulatory approval in 2027.

About Phase II Clinical Study:

Primary Endpoint: Efficacy (complete response at any point in time)

Secondary Endpoint: Efficacy (duration of complete response of 12 months)

Tertiary Endpoint: Safety (serious adverse events directly related to the study drug or study device that do not resolve within 450 days)

Study Procedure: Light-activated Ruvidar

Patient Population: Bacillus Calmette-Guérin ("BCG")-Unresponsive Non-Muscle Invasive Bladder Cancer ("NMIBC") Carcinoma In-Situ ("CIS"), who have failed standard-of-care therapy and are facing radical cystectomy (bladder removal) ("Study II").

About NMIBC:

NMIBC is a form of bladder cancer that is found in the inner layer cells of the bladder and does not invade into or beyond the muscle wall.2 In the United States, bladder cancer is the sixth most common cancer,3 fourth among men,4 and it is estimated that there will be approximately 84,870 new cases of bladder cancer in the U.S. in 2025.4 Historically, 75% of bladder cancer presents as NMIBC.5 In patients with high-risk NMIBC, intravesical BCG remains the first-line standard-of-care; however, approximately one third of patients with NMIBC will not respond to BCG therapy and 50% of those with an initial response will experience recurrence or progression of their disease.6 Current treatment options for BCG-unresponsive patients are very limited and National Comprehensive Cancer Network guidelines recommend cystectomy (partial or complete removal of the bladder).7

About Ruvidar:

Ruvidar is a small molecule activated by energy, intended for the safe and effective destruction of cancer, bacteria and viruses.

(Press release, Theralase, FEB 4, 2026, View Source [SID1234662479])

UroGen Pharma to Present at the Guggenheim Securities Emerging Outlook: Biotech Summit

On February 4, 2026 UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, reported that management will present at the Guggenheim Securities Emerging Outlook: Biotech Summit to take place on February 11-12, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Guggenheim Emerging Outlook: Biotech Summit 2026

Date / Time: February 12, 2026, at 2:30 PM ET
Format: Fireside Chat and 1×1 investor meetings
Location: New York, NY
Webcast Link: here

The webcast from the conference will also be available on UroGen’s corporate website, under Events & Presentations. A replay will be available for approximately 90 days.

(Press release, UroGen Pharma, FEB 4, 2026, View Source [SID1234662480])

CytomX Therapeutics to Present at Upcoming February Conferences

On February 4, 2026 CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, reported that management will participate in the following conferences in February.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Guggenheim Emerging Outlook: Biotech Summit 2026
Date: Wednesday, February 11, 2026
Fireside Chat: 4:30 p.m. ET
Location: New York, NY

World ADC London 2026
Date: Wednesday, February 25, 2026
Presentation: 5:00 p.m. GMT
Location: London, UK

(Press release, CytomX Therapeutics, FEB 4, 2026, View Source [SID1234662466])